

DAFTAR PUSTAKA

- Adella, C.A., Simanjuntak, R.Y., and Adhistry, H.N. Luaran Kanker Ovarium Berdasarkan Modifikasi Glasgow Prognostik Skor, Tesis PPDS I Obstetri dan Ginekologi FK USU. Medan, 2015.
- Argilés, J. M., Busquets, S., & López-Soriano, F. J. (2003). Cytokines in the pathogenesis of cancer cachexia. *Current Opinion in Clinical Nutrition and Metabolic Care*, 6(4), 401–406. <https://doi.org/10.1097/01.mco.0000078983.18774.cc>
- Aziz MF, Andrijono, Saifuddin AB. Buku acuan Nasional Onkologi Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo. Departemen Ginekologi dan ginekologi fakultas kedokteran Indonesia. Edisi pertama. 2006; 469 – 527
- Bae, H. S., Hong, J. H., Ki, K. Do, Song, J. Y., Shin, J. W., Lee, J. M., Lee, J. K., Lee, N. W., Lee, C., Lee, K. W., & Kim, Y. M. (2014). The effect of body mass index on survival in advanced epithelial ovarian cancer. *JKMS*, 29(6), 793–797. <https://doi.org/10.3346/jkms.2014.29.6.793>
- Berek JS, Friedlander M, Hacker NF. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer, in Berek and Hacker's Gynecologic Oncology, 16th Edition. Lippincott Williams & Wilkins, 2020: 2541-2619
- Bugada, D., Allegri, M., Lavand'Homme, P., De Kock, M., & Fanelli, G. (2014). Inflammation-based scores: A new method for patient-targeted strategies and improved perioperative outcome in cancer patients. *BioMed Research International*, 2014. <https://doi.org/10.1155/2014/142425>
- Chang, L. C., Huang, C. F., Lai, M. S., Shen, L. J., Wu, F. L. L., & Cheng, W. F. (2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS ONE*, 13(3), 1–11. <https://doi.org/10.1371/journal.pone.0194993>
- Danukusumo, D. (1991). Akurasi pembedahan kanker ovarium, Tinjauan retrospektif di RS Cipto Mangunkusumo. Simposium Keganasan Ovarium, PTP POGI IX, Bandung
- Di Fiore, F., Lecomte, S., Pop, D., Rigal, O., Hamidou, H., Paillot, B., Ducrotté, P., Lerebours, E., & Michel, P. (2007). Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. *AJG*, 102(11), 2557–2563. <https://doi.org/10.1111/j.1572-0241.2007.01437.x>
- Dinarello, C. A. (2006). The paradox of pro-inflammatory cytokines in cancer. *Cancer and Metastasis Reviews*, 25(3), 307–313. <https://doi.org/10.1007/s10555-006-9000-8>
- Drenberg, C. D., Saunders, B. O., Wilbanks, G. D., Chen, R., Nicosia, R. F., Kruk, P. A., & Nicosia, S. V. (2010). Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. *Gynecologic Oncology*, 117(1), 117–124. <https://doi.org/10.1016/j.ygyno.2009.12.011>

- Elshabrani,S., Farid,A.,El-Beddini, M.,Osman, A., El-Deeb,S. (2012). Evaluation of C-Reactive Protein as a Probable Factor for Cancer Diagnosis, *Life Science Journal*, 9(4):2796-2803
- Foley, O. W., Rauh-Hain, J. A., & del Carmen, M. G. (2013). Recurrent epithelial ovarian cancer: an update on treatment. *Oncology (Williston Park, N.Y.)*, 27(4), 288–298.
- Gupta, D., & Lis, C. G. (2010). Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. *Nutrition Journal*, 9(1), 1–16. <https://doi.org/10.1186/1475-2891-9-69>
- Gupta, D., Lammersfeld, C. A., Vashi, P. G., & Lis, C. G. (2009). A Longitudinal Analysis Investigating the Impact of Improvement in Serum Albumin Scores on Survival in Ovarian Cancer. *Clinical Ovarian Cancer*, 2(2), 106–111. <https://doi.org/10.3816/coc.2009.n.017>
- Han, K. H., Park, N. H., Kim, J. J., Kim, S., Kim, H. S., Lee, M., & Song, Y. S. (2019). The power of the risk of ovarian malignancy algorithm considering menopausal status: A comparison with CA 125 and HE4. *J Gynecol Oncol*, 30(6), 1–9. <https://doi.org/10.3802/jgo.2019.30.e83>
- Harahap, F.P., Sahil, M.F., Edianto, D., Siregar, H.S., Tala, M.R.Z., and Luther, D. Profil Penderita Kanker Epitel Ovarium Berdasarkan Jenis Histologi, Stadium Penyakit, Penatalaksanaan Dan Luaran Ketahanan Hidup 5 Tahun Di Rsup. H. Adam Malik Medan, Tesis PPDS I Obstetri dan Ginekologi FK USU. Medan, 2013.
- Hardiman,A., Noviani, R., Wahidin, M. (2007). Kebijakan dan Pokok – pokok Kegiatan Pengendalian Penyakit Kanker di Indonesia. *Rumah Sakit Kanker Darmas. Indonesia Journal of Cancer*,1(2), 63-72
- Hefler, L. A., Concin, N., Hofstetter, G., Marth, C., Mustea, A., Sehouli, J., Zeillinger, R., Leipold, H., Lass, H., Grimm, C., Tempfer, C. B., & Reinthaller, A. (2008). Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. *Clinical Cancer Research*, 14(3), 710–714. <https://doi.org/10.1158/1078-0432.CCR-07-1044>
- Hefler-Frischmuth, K., Seebacher, V., Polterauer, S., Tempfer, C., Reinthaller, A., & Hefler, L. (2010). The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer. *EJOG*, 149(1), 102–105. <https://doi.org/10.1016/j.ejogrb.2009.12.027>
- Heintz, A.P.M., Odicino,F., Maisonneuve, P., Quinn, M.A., Benedet, J.L., Creasman, W.T., Ngan H.Y.S., Pecorelli. S., Beller. U. (2006), Carcinoma of the ovary. In: Pecorelli S, ed. Twenty-Sixth Annual Report on the Results of Treatment in Gynaecological Cancer. *Int J Gynecol Oncol*, 95(suppl 1),S161-S192
- Hashem, T.A., Shehata, M.A., Alhassanin, S.A., El-Menshawy, S.M., Gohar, S.F.(2020). The prognostic value of Glasgow prognostic score in epithelial ovarian cancer. *Menoufia Med J* 33:699–705. DOI: 10.4103/mmj.mmj_264_19
- Ishizuka, M., Nagata, H., Takagi, K., Horie, T., & Kubota, K. (2007). Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients

- with colorectal cancer. *Annals of Surgery*, 246(6), 1047–1051.
<https://doi.org/10.1097/SLA.0b013e3181454171>
- Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer Statistics , 2009 Both Sexes Female Both Sexes Estimated Deaths. *Ca Cancer J Clin*, 59(4), 1–25. <https://doi.org/10.1002/caac.20073>. Available
- Jordan, S. J., Green, A. C., Whiteman, D. C., Moore, S. P., Bain, C. J., Gertig, D. M., & Webb, P. M. (2008). Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis. *IJC*, 122(7), 1598–1603.
<https://doi.org/10.1002/ijc.23287>
- Kinoshita, T., Ito, H., & Miki, C. (1999). Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. *Cancer*, 85(12), 2526–2531.
[https://doi.org/10.1002/\(SICI\)1097-0142\(19990615\)85:12<2526::AID-CNCR6>3.0.CO;2-3](https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3)
- Kurman, R. J., & Shih, I. M. (2010). The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *Am J Surg Pathol*, 34(3), 433–443.
<https://doi.org/10.1097/PAS.0b013e3181cf3d79>
- Lee, S., Choe, J. W., Kim, H. K., & Sung, J. (2011). High-sensitivity C-reactive protein and cancer. *J Epidemiol*, 21(3), 161–168.
<https://doi.org/10.2188/jea.JE20100128>
- Lee, Suee, Oh, S. Y., Kim, S. H., Lee, J. H., Kim, M. C., Kim, K. H., & Kim, H. J. (2013). Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. *BMC Cancer*, 13, 1–11. <https://doi.org/10.1186/1471-2407-13-350>
- Lee, Y., Miron, A., Drapkin, R., Nucci, MR., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, RW., Cramer, D.W., McKeon, F.D., Crum, C.P. (2007). A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *J Pathol*. 211,26-35. <https://doi.org/10.1002/path>
- Lu, H., Ouyang, W., & Huang, C. (2006). Inflammation, a key event in cancer development. *Molecular Cancer Research*, 4(4), 221–233.
<https://doi.org/10.1158/1541-7786.MCR-05-0261>
- Maas, H. A. A. M., Kruitwagen, R. F. P. M., Lemmens, V. E. P. P., Goey, S. H., & Janssen-Heijnen, M. L. G. (2005). The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: A population-based study. *Gynecologic Oncology*, 97(1), 104–109.
- MacDonald, N. (2012). Terminology in cancer cachexia: Importance and status. *Current Opinion in Clinical Nutrition and Metabolic Care*, 15(3), 220–225.
<https://doi.org/10.1097/MCO.0b013e328352a895>
- Malpica, A. (2008). Grading of ovarian cancer: A histotype-specific approach. *IJGP*, 27(2), 175–181. <https://doi.org/10.1097/PGP.0b013e31816085e0>
- Macciò, A., & Madeddu, C. (2012). Inflammation and ovarian cancer. *Cytokine*, 58(2), 133–147. <https://doi.org/10.1016/j.cyto.2012.01.015>
- McKeown, D. J., Brown, D. J. F., Kelly, A., Wallace, A. M., & McMillan, D. C.

- (2004). The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. *BJC*, 91(12), 1993–1995. <https://doi.org/10.1038/sj.bjc.6602248>
- McMillan, D. C. (2013). The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. *Cancer Treatment Reviews*, 39(5), 534–540. <https://doi.org/10.1016/j.ctrv.2012.08.003>
<https://doi.org/10.1016/j.ygyno.2004.12.026>
- Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., & Sehouli, J. (2016). The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. *Archives of Gynecology and Obstetrics*, 293(4), 695–700. <https://doi.org/10.1007/s00404-016-4035-8>
- Nakamura, K., Nakayama, K., Minamoto, T., Ishibashi, T., Sanuki, K., Yamashita, H., Ono, R., Sasamori, H., Komatsu-Fujii, T., Ishikawa, M., & Kyo, S. (2018). High preoperative Glasgow prognostic score is a negative prognostic factor for patients with endometrial carcinoma. *Molecular and Clinical Oncology*, 429–433. <https://doi.org/10.3892/mco.2018.1551>
- Nodin, B. (2013). Immunohistochemical and molecular studies on ovarian cancer progression and prognosis. Pathology, Lund University
- Nozoe, T., Matono, R., Ijichi, H., Ohga, T., & Ezaki, T. (2014). Glasgow prognostic score (GPS) can be a useful indicator to determine prognosis of patients with colorectal carcinoma. *International Surgery*, 99(4), 512–517. <https://doi.org/10.9738/INTSURG-D-13-00118.1>
- Omichi, C., Nakamura, K., Haraga, J., Masuyama, H., & Hiramatsu, Y. (2016). Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer. *Cancer Medicine*, 5(6), 1074–1080. <https://doi.org/10.1002/cam4.681>
- Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global Cancer Statistics, 2002. *CA Cancer J Clin*, 55(2), 74–108. <https://doi.org/10.3322/canjclin.55.2.74>
- Partheen, K. New Prognostic Markers In Stage III Serous Ovarian Adenocarcinomas.in thesis, Department of Oncology Institute of Clinical Sciences The Sahlgrenska Academy at University of Gothenburg, 2008.
- Peralta,R., Rubery, B.A., Langenfeld, S.C., (2010). Hypoalbuminemia : treatment and medication. *eMedicine Critical Care*, 1-6.
- Proctor, M. J., Horgan, P. G., Talwar, D., Fletcher, C. D., Morrison, D. S., & McMillan, D. C. (2013). Optimization of the systemic inflammation-based Glasgow Prognostic Score: A Glasgow Inflammation Outcome Study. *Cancer*, 119(12), 2325–2332. <https://doi.org/10.1002/cncr.28018>
- Proctor, M. J., Morrison, D. S., Talwar, D., Balmer, S. M., O'Reilly, D. S. J., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2011). An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. *BJC*, 104(4), 726–734.

- <https://doi.org/10.1038/sj.bjc.6606087>
- Raungkaewmanee, S., Tangjitgamol, S., Manusirivithaya, S., Srijaipracharoen, S., & Thavaramara, T. (2012). Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J Gynec Oncol*, 23(4), 265–273. <https://doi.org/10.3802/jgo.2012.23.4.265>
- Reynolds, J. V., Donohoe, C. L., & Ryan, A. M. (2011). Cancer cachexia: Mechanisms and clinical implications. *Gastroenterology Research and Practice*, 2011. <https://doi.org/10.1155/2011/601434>
- Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). (2006). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site
- Schorge, J.O., Hoffman, B.L., Halvorson, L.M., Hamid, C.A., Corton, M.M., Scaffer, J.I. *Epithelial ovarian cancer in Williams Gynecology*, 4th ed. New York, Mc Graw Hill, 2020: p 732-52.
- SEER Stat Fact Sheets: Ovary Cancer. National Cancer Institute. 2014. Available at <http://seer.cancer.gov/statfacts/html/ovary.html>
- Shan, W., & Liu, J. (2009). Inflammation: A hidden path to breaking the spell of ovarian cancer. *Cell Cycle*, 8(19), 3107–3111. <https://doi.org/10.4161/cc.8.19.9590>
- Sharma, R., Hook, J., Kumar, M., & Gabra, H. (2008). Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. *EJC*, 44(2), 251–256. <https://doi.org/10.1016/j.ejca.2007.11.011>
- Sinaga, R., Sahil, M.F., Edianto, D., Tobing, C.L., Siregar, H.S., and Rivani, R. *Rasio Platelet Limfosit Preoperatif Sebagai Faktor Prognostik Kanker Ovarium Epitel*, Tesis PPDS I Obstetri dan Ginekologi FK USU. Medan, 2015.
- Suh, K. S., Park, S. W., Castro, A., Patel, H., Blake, P., Liang, M., & Goy, A. (2010). Ovarian cancer biomarkers for molecular biosensors and translational medicine. *Expert Review of Molecular Diagnostics*, 10(8), 1069–1083. <https://doi.org/10.1586/erm.10.87>
- Suhonen, K. *Prognostic Role of Cell Adhesion Factors and Angiogenesis in Epithelial Ovarian Cancer*. Doctoral Dissertation. Kuopio: University of Kuopio. Clinical Medicine, 2007.
- Tone, A. A., Salvador, S., Finlayson, S. J., Tinker, A. V., Kwon, J. S., Lee, C. H., Cohen, T., Ehlen, T., Lee, M., Carey, M. S., Heywood, M., Pike, J., Hoskins, P. J., Stuart, G. C., Swenerton, K. D., Huntsman, D. G., Gilks, C. B., Miller, D. M., & McAlpine, J. N. (2012). The role of the fallopian tube in ovarian cancer. *Clinical advances in hematology & oncology : H&O*, 10(5), 296–306.
- Toriola, A. T., Grankvist, K., Agborsangaya, C. B., Lukanova, A., Lehtinen, M., & Surcel, H. M. (2011). Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: A longitudinal study. *Annals of Oncology*, 22(8), 1916–1921. <https://doi.org/10.1093/annonc/mdq694>

- Wang, C. S., & Sun, C. F. (2009). C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. *Chang Gung Med J*, 32(5), 471–482.
- Zhang, J., & Yu, K. F. (1998). What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA*, 280(19), 1690–1691. <https://doi.org/10.1001/jama.280.19.1690>
- Zhang, W., Ye, B., Liang, W., & Ren, Y. (2017). Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer. *Scientific Reports*, 7(1), 1–8. <https://doi.org/10.1038/s41598-017-10328-8>
- Zhu, J., Wang, H., Liu, C. C., Lu, Y., & Tang, H. (2016). The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. *Journal of Cancer Research and Clinical Oncology*, 142(11), 2339–2345. <https://doi.org/10.1007/s00432-016-2228-y>